ArticleArthritis care & research2026
The Painful Truth: The Relationship Between Nonarticular Pain and Patient Global Assessment Before and After Initiating a New Disease-Modifying Antirheumatic Drug for Active Rheumatoid Arthritis.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveNonarticular pain (NAP) may contribute to patient global assessment (PtGA), confound disease activity assessment, and influence treatment decisions. Our aims were to (1) evaluate the association between NAP and PtGA in adults with active rheumatoid arthritis (RA) starting a new disease-modifying antirheumatic drug (DMARD) and (2) determine the extent to which this relationship is mediated by pain intensity.
methodsWe enrolled adults with active RA initiating a new DMARD. Participants indicated NAP on a body pain diagram (0-19 sites) and completed assessments of PtGA and pain intensity. To evaluate the association between NAP and PtGA, adjusted multivariable linear regression was performed. Mediation analyses using linear regression models examined whether this association was mediated by pain intensity at baseline and at three months separately. All models were adjusted for potential confounders.
resultsThe 197 participants were mostly female (83.8%), with a mean age of 55.1 (SD 14.4) years, a mean disease duration of 10.6 (SD 12.6) years, and a mean Clinical Disease Activity Index score of 23.9 (SD 14.6). NAP was reported by 92.9% at baseline and by 84.8% at three months. At baseline, each site of NAP (0-19) was associated with a 0.20-point higher PtGA (β = 0.20, 95% confidence interval 0.12-0.28). Pain intensity mediated 61.8% of this association. Similar findings were observed at three months.
conclusionThere was a significant linear relationship between NAP and PtGA, most of which could be explained by pain intensity. These findings raise awareness of NAP and its added burden of worse perceived health status in RA. This may help prevent unnecessary DMARD treatment changes and increase specificity in treatment of different pain types.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.